TABLE OF CONTENTS
Volume 74, Issue 2 (August 2003)
Pharmacodynamics and Drug Action |
Pharmacokinetics and Drug Disposition |
Pharmacogenetics and Genomics |
Letters to the Editor
Commentary
Clinical Pharmacology & Therapeutics annual report 2002
C. Michael Stein MD
Clin Pharmacol Ther 74: 99-101; doi:10.1016/S0009-9236(03)00149-8
Pharmacodynamics and Drug Action
Side effects of opioids during short-term administration: Effect of age, gender, and race
M. Soledad Cepeda MD, PhD, John T. Farrar MD, MSCE, Mona Baumgarten PhD, Ray Boston PhD, Daniel B. Carr MD and Brian L. Strom MD, MPH
Clin Pharmacol Ther 74: 102-112; doi:10.1016/S0009-9236(03)00152-8
Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain
Maria Burian MD, Irmgard Tegeder MD, Maic Seegel and Gerd Geisslinger MD, PhD
Clin Pharmacol Ther 74: 113-120; doi:10.1016/S0009-9236(03)00165-6
Pharmacokinetics and Drug Disposition
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice
David J. Greenblatt, Lisa L. von Moltke, Jerold S. Harmatz, Gengsheng Chen, James L. Weemhoff, Cheng Jen, Charles J. Kelley, Barbara W. LeDuc and Miguel A. Zinny
Clin Pharmacol Ther 74: 121-129; doi:10.1016/S0009-9236(03)00118-8
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
Ulrike Werner PhD, Dierk Werner MD, Thomas Rau MD, Martin F. Fromm MD, Burkhard Hinz PhD and Kay Brune MD
Clin Pharmacol Ther 74: 130-137; doi:10.1016/S0009-9236(03)00120-6
Pharmacokinetic drug interactions in children taking oxcarbazepine
William M. Sallas PhD, Slavica Milosavljev PhD, Joseph D'Souza PhD and Mohammad Hossain PhD
Clin Pharmacol Ther 74: 138-149; doi:10.1016/S0009-9236(03)00124-3
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe
Anup K. Majumdar PhD, Jacqueline B. McCrea PharmD, Deborah L. Panebianco MS, Michael Hesney MS, James Dru MS, Marvin Constanzer BS, Michael R. Goldberg MD, Gail Murphy MD, Keith M. Gottesdiener MD, Christopher R. Lines PhD, Kevin J. Petty MD and Robert A. Blum PharmD
Clin Pharmacol Ther 74: 150-156; doi:10.1016/S0009-9236(03)00123-1
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites
Miranda Verschraagen PharmD, Epie Boven MD, PhD, Rita Ruijter, Kasper van der Born BSc, Johannes Berkhof PhD, Frederick H. Hausheer MD and Wim J. F. van der Vijgh PhD
Clin Pharmacol Ther 74: 157-169; doi:10.1016/S0009-9236(03)00150-4
Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers
John S. Markowitz PharmD, C. Lindsay DeVane PharmD, Kenneth D. Chavin MD, PhD, Robin M. Taylor BS, Ying Ruan BS and Jennifer L. Donovan PhD
Clin Pharmacol Ther 74: 170-177; doi:10.1016/S0009-9236(03)00148-6
Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia
Mia Hedman MB, Pertti J. Neuvonen MD, Mikko Neuvonen MSc and Marjatta Antikainen MD
Clin Pharmacol Ther 74: 178-185; doi:10.1016/S0009-9236(03)00153-X
Pharmacogenetics and Genomics
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers
Julia Kirchheiner MD, Dirk Kudlicz BS, Christian Meisel MD, Steffen Bauer PhD, Ingolf Meineke PhD, Ivar Roots MD and Jürgen Brockmöller MD
Clin Pharmacol Ther 74: 186-194; doi:10.1016/S0009-9236(03)00121-8
Letters to the Editor
Rational prescribing of essential medicines
Marcus M. Reidenberg MD
Clin Pharmacol Ther 74: 195; doi:10.1016/S0009-9236(03)00122-X
MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa
Paul K. Chelule MMedSc, Michelle Gordon MMedSc, Thesla Palanee MMedSc, Taryn Page BTech, Anisa Mosam FC Derm, H. M. Coovadia MD and Sharon Cassol PhD
Clin Pharmacol Ther 74: 195-196; doi:10.1016/S0009-9236(03)00151-6
